Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 721
Aptamer sequence: GGAACCCAACUAGGCGUUUGAGGGGAUUCGGCCACGGUAACAACCCCUC
Target unique ID: 439153
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_668 N Molecule 1,4-Dihydronicotinamide adenine dinucleotide 37 nM 20 mM HEPES (pH 7.5), 300 mM KC1, and 5 mM MgC12 at room temperature 11539282
Structure information of aptamer
Aptamer Sequence: GGAACCCAACUAGGCGUUUGAGGGGAUUCGGCCACGGUAACAACCCCUC
The optimal secondary structure in dot-bracket notation: .((((((.....)).))))((((((.....((....)).....))))))
The centroid secondary structure in dot-bracket notation: .((((((.....)).))))((((((.....((....)).....))))))
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_668 Description N
Aptamer chemistry RNA Length 49 nt
GC content 59.2% Molecular weight 15,748.43 Da
Molarity of 1 μg/μl solution 63.50 μM Number of G-quadruplexes 2
G-Score 19 Function Targeted binding
Sequence GGAACCCAACUAGGCGUUUGAGGGGAUUCGGCCACGGUAACAACCCCUC
Applications Binding to Flavin and Nicotinamide Redox Cofactors
Target information
Type Detail Type Detail
PubChem ID 439153 Molecular name 1,4-Dihydronicotinamide adenine dinucleotide
Molecular formula C21H29N7O14P2 Molecular weight 665.4
IUPAC name [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate InChIKey BOPGDPNILDQYTO-NNYOXOHSSA-N
LogP -2.686 Topological polar surface area 317.62
Hydrogen bond acceptor 18 Hydrogen bond donor 8

Synonym(s):
NADH; DPNH; beta-NADH; beta-DPNH; Dihydrocozymase; 58-68-4; Coenzyme I, reduced; Cozymase I, reduced; 1,4-Dihydronicotinamide adenine dinucleotide; NADH2; Dihydrocodehydrogenase I; Reduced codehydrogenase I; dihydronicotinamide adenine dinucleotide; Codehydrase I, reduced; Dihydronicotinamide-adenine dinucleotide; Reduced nicotinamide adenine diphosphate; Dihydronicotinamide mononucleotide; Codehydrogenase I, reduced; Reduced diphosphopyridine nucleotide; Reduced nicotinamide-adenine dinucleotide; UNII-4J24DQ0916; 606-68-8; Reduced Nicotinamide Adenine Dinucleotide; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; CHEBI:16908; 4J24DQ0916; nicotinamide adenine dinucleotide (reduced); Adenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide; Adenosine 5'-(trihydrogen pyrophosphate), 5'-5'-ester with 1,4-dihydro-1beta-D-ribofuranosylnicotinamide; nadh hydride; coenzyme-I; b-dpnh; NAD reduced form; EINECS 200-393-0; MFCD00036200; ENADA; b-NADH; Nicotinamide - adenine dinucleotide, reduced; bmse000054; SCHEMBL8187; GTPL4487; CHEMBL1234616; DTXSID30889320; ZINC8215403; DB00157; [(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-[[(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-phosphinic acid; Adenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide (9CI); Adenosine 5'-(trihydrogen pyrophosphate), 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (8CI); adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] dihydrogen diphosphate}; Adenosine pyrophosphate, 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (7CI); Nicotinamide-adenine dinucleotide, reduced; 6453-EP1441224A2; 6453-EP2269610A2; 6453-EP2272834A1; 6453-EP2275414A1; 6453-EP2277876A1; 6453-EP2277898A2; 6453-EP2284149A1; 6453-EP2289510A1; 6453-EP2292614A1; 6453-EP2292630A1; 6453-EP2295417A1; 6453-EP2295435A1; 6453-EP2298312A1; 6453-EP2298743A1; 6453-EP2301929A1; 6453-EP2301935A1; 6453-EP2305674A1; 6453-EP2308960A1; 6453-EP2316457A1; 6453-EP2316458A1; 6453-EP2316825A1; 6453-EP2316826A1; 6453-EP2316827A1; 6453-EP2316828A1; 6453-EP2374895A1; C00004; Q26987453; beta-Nicotinamide adenine dinucleotide reduced disodium salt; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate; Adenosine 5'-(trihydrogen diphosphate), 5'->'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide; Adenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide; Adenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide

Activity data
Interaction ID 721
Target type Molecule
Target unique ID 439153
Activity 37 nM
Binding Conditions/Buffer

20 mM HEPES (pH 7.5), 300 mM KC1, and 5 mM MgC12 at room temperature
Assay

Equilibrium gel filtration measurement of solution Kd's of NMN aptamer
PubMed ID 11539282
Interaction ID 722
Target type Molecule
Target unique ID 5892
Activity 2.5 nM
Binding Conditions/Buffer

20 mM HEPES (pH 7.5), 300 mM KC1, and 5 mM MgC12 at room temperature
Assay

Equilibrium gel filtration measurement of solution Kd's of NMN aptamer
PubMed ID 11539282
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_647 RNA GGAUCCCGACUGGCGAGAGCCAGGUAACGAAUGGAUCC 57.14%
Apta_647 RNA GGAUCCCGACUGGCGAGAGCCAGGUAACGAAUGGAUCC 57.14%
Apta_778 DNA GAAGACGAGCGGCGAGTGTTATTACGCTTGGAAACAACCCC 53.06%
Apta_778 DNA GAAGACGAGCGGCGAGTGTTATTACGCTTGGAAACAACCCC 53.06%
Apta_601 RNA GGGAAUUCCGCGUGUGCGCCGCGGAAGAGGGAAUAUAGAGGCCAGCACAUAGUGAGGCCCUCCUCCC 52.24%
Apta_460 RNA GGAUGGCAGCGGAGAGUUGCUUGGAAUGCGUUAUAGUCUCUUAGGUGUGUACAGCCCACACCACUCUCC 52.17%
Apta_984 RNA GGGAGGACGAUGCGGCGUAUUGCGCGAGGAUUAUCCGCUCAUCGUUGUUGUUGUGCAGACGACUCGCCCGA 52.11%
Apta_453 RNA GGGCUAGCUGAUCGUACCAGUAGCGUGGCCUGGGGGGCCUAGUCGUGCGAUACUAACAGCUAACACCC 51.47%
Apta_365 RNA GGACCUAUGCAGUAGCCAGUGUGGACUGGGCUGCCCCCCC 51.02%
Apta_132 RNA GGGAGGACGAUGCGGCGUUUCCUCUGGUUCGUCCCCAGACGACUCGCCCGA 50.98%
Apta_54 RNA GUACAACACAUCAUUACGGCUGCUAUUGGCUCCAAGCGUCUUUCUCCCUGGUCAAUAGUCCAGCCACCACG 50.70%
Apta_383 RNA GGCGUGACCUGAUGAGUCACGCUAAGGAGGAUUUCCGAAAGCGGCUACGGUCCGCCAGUGUUACGAAACGUUCCC 50.67%
Apta_394 RNA GGGCGAAUUCAACUGCCAUCUAGGCAGUAACCAGGAGUUAGUAGGACAAGUUUCGUCC 50.00%
Apta_427 RNA GAAGCUUUCACACAACAAGGCCCGGGACUGUAUUAGGGAAAUUAGAGUACAGACAGUCGCCGUGGGUCGAAUUCCGCUCA 50.00%
Apta_707 RNA GGCCUAAAACAUACCAGAUUUCGAUCUGGAGAGGUGAAGAAUUCGACCACCUAGGCCGGU 50.00%
Apta_496 RNA GGGCUAGCUGAUCGUACCCAGUAGCGUGGCAUGGGGUGCCUAGUCGGGCGAUACUAACAGCUAACACCC 49.28%
Apta_2 RNA GGGCUUCUCUGGUUAGACCAGAUUUGAGCCUGGGAGCUCUCUGGCUAACUAGGGAACCC 49.15%
Apta_135 RNA GGGAGGACGAUGCGGAUUCUGGUUACUGGCCGCCCCAGACGACUCGCCCGA 49.02%
Apta_91 RNA GAUAACCUCGAUGCGACGUUCGGCCUCAAAAUCAA 48.98%
Apta_218 RNA AGCCGCGAGGGGAGGGAUAGGGUAGGGCGCGGCU 48.98%

ABOUT

AptaDB is an online database we developed to integrate comprehensive information about aptamer.
The detail of this database is described here:

HELP CENTER

>Contact us
>LMMD Group
>School of Pharmacy

DEV TOOL
Page last updated at 2022-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 43982
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.